Steve Eisman To Launch New Fund In January

Oct 18 2011 | 1:59pm ET

Steve Eisman, the hedge-fund manager who made his name betting against subprime mortgages, will launch a new fund—Emrys Partners—in January.

Four people “briefed on the matter” told Bloomberg Eisman will partner with Rocwood Capital Managment’s Jon Kalikow, Goldman Sachs Group’s Ed Cabral and JAT Capital Management’s Mark Weiner on the long-short fund which will invest in stocks and bonds across industries.

Eisman, formerly with Connecticut-based FrontPoint Partners, left that company earlier this year as allegations a healthcare fund portfolio manager at the firm—Chip Skowron—had traded on insider information caused investors to bail.

An unnamed investor told Bloomberg that Eisman’s Financial Services fund had lost between 14% and 18% at the time he left. Eisman's funds had shrunk to $750 million in January from more than $1 billion in 2010. According to AR magazine, his Financial Horizons Fund, which invests in the stocks and bonds of financial services companies, fell 3.2% in Q1 2011 after having fallen 7.7% in 2010.

It was the Financial Horizons Fund that brought Eisman to prominence—it returned 81% in 2007 thanks to a bet on subprime mortgages, attracting the attention of author Michael Lewis. who included Eisman in his book The Big Short: Inside the Doomsday Machine, as one of the few people who saw the subprime crisis coming.

Reports have been swirling since June that Eisman planned to start his own firm with a team of six or so employees from FrontPoint.


In Depth

GSAM's Papagiannis: Liquid Alternatives For The Long Run

Apr 21 2017 | 8:44pm ET

Interest in liquid alternatives cooled a bit last year amid a broad shift in investor...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Debunking Conventional Investment Wisdom (Part II)

Apr 17 2017 | 5:56pm ET

The alternative investment industry is currently replete with buzzwords around data...

 

From the current issue of